Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470496 | 0.96 | CYP24A1 (0.33) | CYP24A1MAPT | |
| SCHEMBL3487865 | 0.88 | SMN1; SMN2 (0.35) | CYP24A1MAPT | |
| SCHEMBL3487861 | 0.86 | SMN1; SMN2 (0.35) | CYP24A1MAPT | |
| SCHEMBL3488389 | 0.82 | SMN1; SMN2 (0.35) | MAPT | |
| SCHEMBL3488388 | 0.80 | SMN1; SMN2 (0.35) | MAPT | |
| SCHEMBL3488288 | 0.76 | CA12 (0.41) | MAPT | |
| SCHEMBL5613807 | 0.73 | MTOR (0.36) | MAPT | |
| SCHEMBL3487236 | 0.72 | MAPT (0.43) | MAPT | |
| SCHEMBL3486901 | 0.72 | SMN1; SMN2 (0.38) | MAPT | |
| SCHEMBL5606506 | 0.72 | NR1H2 (0.39) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | CYP24A1 302/4885MAPT 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.